home / stock / ayla / ayla message board
Subject | By | Source | When |
---|---|---|---|
What happened to Ayala stock today 1/20/23? | bme | investorshub | 01/20/2023 2:40:36 PM |
The deal doubles the amount of catalysts for | StockLogistics | investorshub | 10/19/2022 6:03:16 PM |
6:33a ET 10/19/2022 - Benzinga | StockLogistics | investorshub | 10/19/2022 11:28:48 AM |
Ayala Pharmaceuticals Announces Fast Track Designation Granted by | subslover | investorshub | 09/27/2022 12:17:23 PM |
even Wainwright PT still $12 https://www.americanbankingnews.com/2022/08/18/hc-w | TheFinalCD | investorshub | 08/24/2022 6:11:00 PM |
I like the PT's > 15.00+ | crudeoil24 | investorshub | 08/24/2022 5:43:42 PM |
https://www.marketbeat.com/stocks/NASDAQ/$AYLA/ | TheFinalCD | investorshub | 08/24/2022 5:39:23 PM |
$AYLA up 24% @ 1.67 | crudeoil24 | investorshub | 08/24/2022 4:56:35 PM |
Noble Financial analyst Robert LeBoyer reiterated a Buy | crudeoil24 | investorshub | 08/24/2022 4:40:32 PM |
Ayala Pharmaceuticals Selected to Present Efficacy and Tolerability | crudeoil24 | investorshub | 08/24/2022 4:39:18 PM |
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company | crudeoil24 | investorshub | 08/24/2022 4:37:18 PM |
znewcar1: AYLA 94% v101M c1.69 f14,1M H2.42 ML=YL.7 | znewcar1 | investorshangout | 07/26/2022 8:22:47 PM |
News, Short Squeeze, Breakout and More Instantly...
Ayala Pharmaceuticals Inc. Company Name:
AYLA Stock Symbol:
NASDAQ Market:
Successful End-of-Phase 2 meeting with FDA regarding AL102 for the treatment of desmoid tumors Enrollment in the Phase 3 segment of RINGSIDE trial evaluating AL102 continuing globally as planned Definitive merger agreement with Biosight, expected to close near end of Q3 2023 REHOVOT...
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a publicly-traded clinical-stage oncology company, today announced that it will present posters on its gamma secretase inhibitors AL102 and AL101 at the European Societ...
Company confirms FDA agreement on key elements of the Phase 3 segment of ongoing RINGSIDE study, including dosing regimen of 1.2mg once daily Enrollment in Phase 3 continuing as planned REHOVOT, Israel & MONMOUTH JUNCTION, N.J., July 05, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmace...